查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949598

非侵入性產前檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依產品類型、檢測類型、方法、應用、最終用戶、地區及競爭格局分類，2021-2031年）

Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非侵入性產前檢測 (NIPT) 市場預計將從 2025 年的 52.5 億美元成長到 2031 年的 82.3 億美元，複合年成長率達到 7.78%。

非侵入性產前檢測 (NIPT) 是一種先進的篩檢技術，可透過檢測母體血液中存在的遊離胎兒 DNA 來識別染色體非整倍體，例如 21 三體症候群、18 三體症候群和 13 三體症候群。推動該市場成長的主要因素是全球孕婦平均年齡的成長，以及人們對安全、非侵入性的替代傳統侵入性診斷方法（例如羊膜穿刺術）的明顯偏好。此外，檢測能力的不斷提升，使其能夠涵蓋更廣泛的疾病，也促進了其應用。例如，診斷和實驗室醫學協會 (ADLM) 在 2025 年報告稱，研究證實了這些篩檢測試的廣泛效用，例如在 2.1% 的妊娠中檢測到巨細胞病毒DNA，凸顯了其在全面評估胎兒健康方面的潛力。

市場概覽
預測期 2027-2031
市場規模：2025年 52.5億美元
市場規模：2031年 82.3億美元
複合年成長率：2026-2031年 7.78%
成長最快的細分市場 和諧
最大的市場 北美洲

儘管有這些有利因素，但檢測成本高昂和報銷制度不統一仍然是市場推廣的重大障礙。這些經濟障礙限制了公眾，特別是開發中國家和低收入群體獲得檢測的機會，並阻礙了非侵入性產前檢測（NIPT）成為廣泛產前保健的標準檢測項目。因此，這些經濟障礙阻礙了全球市場達到完全飽和。

市場促進因素

對於診斷服務提供者而言，在非侵入性產前檢測 (NIPT) 領域拓展全球業務和提升能力，主要市場參與者之間的策略聯盟與合作至關重要。透過收購和與區域實驗室建立合作關係，主要企業正在整合市場、強化分銷網路，並將專業檢測技術納入其產品組合。這種整合將使他們能夠為不同的患者群體提供高效的產前篩檢服務，並加速推廣全面的女性健康解決方案。例如，LabCorp 在 2025 年 2 月發布的「2024 年第四季及全年財務表現」報告中指出，該公司在 2024 年完成了 10 項交易，鞏固了其作為醫療保健系統值得信賴的合作夥伴的地位。這顯著增強了該公司在女性健康等高成長領域的實力。

全球平均生育年齡的上升是推動染色體異常篩檢需求持續成長的主要因素。隨著社會經濟因素不斷推遲生育年齡，高齡生產帶來的染色體異常臨床風險增加，使得可靠、非侵入性的胎兒健康評估變得特別重要。美國疾病管制與預防中心 (CDC) 於 2025 年 4 月發布的報告《胎兒出生：2024 年初步數據》強調了這一重要的人口結構變化，預測 2024 年 40-44 歲女性的生育率將比前一年成長 2%。高危險妊娠的增加與產前檢測使用率的提高有直接關係。 2025 年 2 月，Myriard Genetics 公司報告稱，其產前檢測收入比上一年成長了 12%，這反映了推動這些重要篩檢檢測需求的強勁人口壓力。

市場挑戰

全球無創產前檢測 (NIPT) 市場受到高昂檢測費用以及不同地區和保險公司報銷政策不一致的嚴重限制。儘管 NIPT 的準確性已得到認可，但高昂的自付費用對很大一部分人群構成了重大障礙，尤其是在開發中國家以及保險覆蓋範圍有限或被拒保的中等風險妊娠中。這種經濟差距阻礙了 NIPT 成為普遍的醫療標準，使其實際上成為加值服務，而非所有孕婦均可享受的常規醫療程序。

因此，市場滲透率仍然不均衡，成長主要集中在擁有全額保險的人群中。 2025年，德國醫學協會指出了這種差異，並透露，由於經濟限制，26歲以下孕婦中只有約25%使用NIPT服務，而擁有完善保險的年齡層的使用率則顯著更高。這種差異表明，經濟因素和支付方政策的不一致直接限制了NIPT市場的規模發展及其在更廣泛的產前保健領域達到飽和的能力。

市場趨勢

將該檢測範圍擴大至一般風險妊娠標誌著市場發生了根本性轉變，消費群從高風險妊娠人群轉向了普通孕婦群體。這項轉變的促進因素包括：所有孕婦（無論年齡大小）篩檢的日益標準化，以及在年輕族群中臨床療效不斷得到檢驗。這種廣泛的應用導致檢測量迅速成長，成為推動產業擴張的新主要動力。例如，Natera公司在其2025年11月發布的「2025年第三季財務業績」中報告稱，該公司已處理了約893,600份檢測樣本。這比前一年成長了15.2%，主要得益於這些篩檢檢測在更廣泛的患者群體中的廣泛應用。

同時，隨著綜合多基因檢測技術的不斷發展，該產業也持續演進，其診斷能力已超越了傳統的染色體異常檢測。製造商們正致力於研發創新檢測方法，以識別傳統非侵入性檢測方法無法檢測到的特定單基因疾病和罕見疾病，從而滿足早期懷孕階段對更高診斷準確性的臨床需求。這項技術進步使得複雜遺傳疾病的篩檢成為可能，並提供更深入的基因訊息，從而促進早期療育。作為這項進步的象徵，Natera公司於2025年10月宣布，將把其單基因檢測範圍擴展至20個基因，顯著提升其檢測難以發現的純合突變和嚴重早發性疾病的能力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球無創產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（耗材、設備）
    • 按測試類型（Materuni 21、Harmony、Panorama、Verifi、NIFTY、其他）
    • 透過方法（超音波、篩檢篩檢、無細胞DNA母體血漿檢測、母體血胎兒細胞檢測、其他）
    • 依應用（三體症候群、微缺失症候群等）
    • 依最終用戶（診斷檢查室、醫院等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美無創產前檢測 (NIPT) 市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲無創產前檢測 (NIPT) 市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區非侵入性產前檢測（NIPT）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲無創產前檢測 (NIPT) 市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球無創產前檢測（NIPT）市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • YOURGENE HEALTH Plc
  • Illumina, Inc.
  • Natera, Inc.
  • F.Hoffman La Roche Ltd.
  • Perkin Elmer Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins LifeCodex GmbH
  • Progenity, Inc.
  • Genesis Genetics
  • Quest Diagnostics Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4669

The Global Non-invasive Prenatal Testing (NIPT) Market is projected to expand from USD 5.25 Billion in 2025 to USD 8.23 Billion by 2031, achieving a CAGR of 7.78%. NIPT serves as an advanced screening technique that examines cell-free fetal DNA found in maternal blood to identify chromosomal aneuploidies, including trisomy 21, 18, and 13. The primary catalysts for this market growth are the rising average maternal age worldwide and a distinct preference for safe, non-invasive alternatives to traditional invasive diagnostic procedures like amniocentesis. Furthermore, the continual enhancement of testing capabilities to cover a wider array of conditions supports increased adoption. For instance, the Association for Diagnostics & Laboratory Medicine reported in 2025 that research confirmed the expanded utility of these screenings by detecting Cytomegalovirus DNA in 2.1% of pregnancies, highlighting the potential for comprehensive fetal health assessments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.25 Billion
Market Size 2031USD 8.23 Billion
CAGR 2026-20317.78%
Fastest Growing SegmentHarmony
Largest MarketNorth America

Despite these positive drivers, the market encounters a substantial obstacle regarding the high price of testing and variable reimbursement policies. This financial hurdle limits access for the general public, especially within developing nations and lower-income demographics, thereby preventing NIPT from becoming a universally implemented standard in routine prenatal care. Consequently, these economic barriers impede the global market's ability to reach full saturation.

Market Driver

Strategic partnerships and collaborations among leading market players are essential for broadening the global reach and capabilities of diagnostic providers in the NIPT sector. By acquiring regional laboratories and forming alliances, major companies are consolidating the market to strengthen distribution networks and incorporate specialized testing technologies into their portfolios. This consolidation facilitates the efficient delivery of prenatal screening services to diverse patient populations and accelerates the availability of comprehensive women's health solutions. For example, Labcorp announced in its 'Fourth Quarter and Full Year 2024 Results' in February 2025 that it completed 10 transactions throughout 2024 to solidify its position as a trusted partner to health systems, significantly reinforcing its presence in high-growth areas such as women's health.

The rising average maternal age globally serves as a primary catalyst for the sustained demand for chromosomal aneuploidy screening. As delayed childbearing trends continue due to changing socio-economic factors, the increased clinical risk of chromosomal abnormalities in older mothers necessitates reliable, non-invasive fetal health evaluations. According to the CDC's 'Births: Provisional Data for 2024' report released in April 2025, the birth rate for women aged 40-44 rose by 2% in 2024, highlighting this significant demographic shift. This increase in higher-risk pregnancies correlates directly with higher utilization rates of prenatal diagnostics; Myriad Genetics reported in February 2025 that prenatal testing revenue grew 12% year-over-year, reflecting the strong uptake of these essential screenings driven by demographic pressures.

Market Challenge

The Global Non-invasive Prenatal Testing (NIPT) Market is significantly constrained by high testing costs and the absence of consistent reimbursement policies across various regions and insurance providers. Although NIPT is acknowledged for its accuracy, substantial out-of-pocket expenses create a severe barrier to entry for a large segment of the population, particularly in developing economies and among average-risk pregnancies where insurance coverage is frequently denied or limited. This financial disparity prevents the test from becoming a universal standard of care, effectively categorizing it as a premium service rather than a routine medical procedure available to all expectant mothers.

As a result, market penetration remains uneven, with growth heavily concentrated in demographics that benefit from full financial coverage. In 2025, the German Medical Association highlighted this discrepancy, revealing that only approximately 25% of pregnant women under the age of 26 accessed NIPT services due to funding limitations, compared to significantly higher adoption rates in age groups with established reimbursement coverage. This divide illustrates how economic factors and inconsistent payer policies directly restrict the scalable expansion of the NIPT market, limiting its potential to reach saturation in the broader prenatal care sector.

Market Trends

The expansion of testing coverage to include average-risk pregnancies marks a fundamental shift in the market, transitioning the consumer base from exclusively high-risk cases to the broader general population. This evolution differs from demographic drivers as it relies on the normalization of screening as a standard routine for all expectant mothers regardless of age, supported by increasing clinical validation for younger demographics. The uptake in this wider segment is rapidly accelerating test volumes, creating a new primary engine for industry expansion. Evidencing this mass-market adoption, Natera reported in its 'Third Quarter 2025 Financial Results' in November 2025 that the company processed approximately 893,600 tests, a 15.2% increase year-over-year, driven largely by the robust penetration of these screenings into broader patient categories.

Concurrently, the industry is advancing through the development of comprehensive multi-gene panel testing, which extends diagnostic capabilities beyond standard aneuploidy detection. Manufacturers are innovating assays that identify specific single-gene disorders and rare conditions previously undetectable via non-invasive methods, thereby addressing the clinical need for higher diagnostic yield in early pregnancy. This technological evolution enables the screening of complex inherited conditions, providing deeper genetic insights that facilitate earlier interventions. Highlighting this advancement, Natera announced in October 2025 the expansion of its single-gene testing panel to cover 20 genes, significantly enhancing its capability to detect challenging homozygous mutations and severe early-onset disorders.

Key Market Players

  • YOURGENE HEALTH Plc
  • Illumina, Inc.
  • Natera, Inc.
  • F.Hoffman La Roche Ltd.
  • Perkin Elmer Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins LifeCodex GmbH
  • Progenity, Inc.
  • Genesis Genetics
  • Quest Diagnostics Incorporated

Report Scope

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type

  • Consumables
  • Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type

  • Materni 21
  • Harmony
  • Panaroma
  • Verifi
  • NIFTY
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Method

  • Ultrasound Detection
  • Biochemical Screening Testing
  • Cell-Free DNA Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Application

  • Trisomy
  • Microdeletion Syndrome
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By End User

  • Diagnostic Laboratories
  • Hospitals
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Consumables, Instruments)
    • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
    • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
    • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
    • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Test Type
    • 6.2.3. By Method
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Method
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Method
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Method
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Test Type
    • 7.2.3. By Method
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Method
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Method
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Method
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Method
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Method
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Test Type
    • 8.2.3. By Method
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Method
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Method
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Method
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Method
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Method
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Test Type
    • 9.2.3. By Method
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Method
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Method
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Method
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Test Type
    • 10.2.3. By Method
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Method
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Method
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Method
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. YOURGENE HEALTH Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Illumina, Inc.
  • 15.3. Natera, Inc.
  • 15.4. F.Hoffman La Roche Ltd.
  • 15.5. Perkin Elmer Inc.
  • 15.6. Laboratory Corporation of America Holdings
  • 15.7. Eurofins LifeCodex GmbH
  • 15.8. Progenity, Inc.
  • 15.9. Genesis Genetics
  • 15.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer